Xcout Intel
Exosome Diagnostics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Exosome Diagnostics, Inc. among diagnostics companies — ranked by similarity to what Exosome Diagnostics, Inc. actually does, not by market-cap band.
Subscribe to see Exosome Diagnostics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc. is a molecular diagnostics company located in Massachusetts, United States. The company specializes in developing biofluid-based liquid biopsy tests, such as the ExoDx Prostate test, for use in personalized medicine and oncology.
Exosome Diagnostics, Inc. at a glance
Exosome Diagnostics, Inc. is a diagnostics company headquartered in United States. Its most recent funding round raised $30.3M in June 2017. Xcout tracks 11 named people at Exosome Diagnostics, Inc., including Michael K. McGarrity (Chief Executive Officer, Director).
Exosome Diagnostics, Inc. leadership
- Michael K. McGarrityChief Executive Officer, Director
- Ron KalfusInterim Chief Financial Officer
- John BellanoChief Commercial Officer
- Joseph SolleeExecutive Vice President of Corporate Development and General Counsel
- Kim LerouxExecutive Vice President, Revenue Cycle Management
- Koen HoffmanChairman and Independent Director, representing Ahok BV
5 more named people on record for Exosome Diagnostics, Inc., with roles, board committees and tenure — see the full roster →
Exosome Diagnostics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $30.3M | — | |
| SEC Form D filing | $15.5M | — | |
| Series B | $44.7M | — | |
| SEC Form D filing | $1.5M | — | |
| Series A | $20M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Exosome Diagnostics, Inc. competitors
Ranked by semantic similarity — how close each company is to Exosome Diagnostics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
ExosomeDx (Exosome Diagnostics) develops noninvasive liquid-biopsy diagnostics based on RNA carried in exosomes, including the ExoDx Prostate test for assessing prostate-cancer risk. Its products serve urologists, oncologists, laboratories, and patients by supporting clinical decision-making without relying solely on invasive biopsy.
Biotechnology
Nexosome Oncology Holdings, Inc. develops blood tests for early-stage cancer detection using patented extracellular vesicle proteomics and AI/ML biomarker discovery. The company serves patients and healthcare partners by providing highly accurate diagnostic tools.
Biotechnology
EcoGenome LLC is a biotechnology company that develops diagnostic tests and kits for cancer, specifically focusing on prostate cancer. The company identifies individual tumor genetic vulnerabilities to help inform precise therapy planning and treatment choices for patients.
Biotech
Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
Biotech
MDxHealth SA is a commercial-stage precision diagnostics company specializing in urological solutions, with operations spanning the United States, the Netherlands, Belgium, Spain, Poland, Italy, the wider European Union, and various other international regions. The firm offers advanced genomic tests for prostate cancer, including SelectMDx, a non-invasive urine diagnostic, and ConfirmMDx, an epigenetic test. These innovative tools enable medical professionals to identify clinically significant prostate cancer while reducing the need for invasive procedures that carry potential complications. Incorporated in 2003, MDxHealth SA is headquartered in Herstal, Belgium, having changed its name from OncoMethylome Sciences SA in October 2010.
Biotechnology
Predicine Holdings Ltd provides next-generation liquid biopsy platforms and molecular profiling services for cancer research and precision medicine. The company utilizes proprietary blood- and urine-based assays to analyze circulating tumor DNA and RNA, serving biopharmaceutical partners and clinical researchers in oncology drug development and clinical trials.
Biotech
Precede Biosciences is a biotechnology company developing blood-based liquid-biopsy technologies for molecular profiling of cancer. Its tests are intended to support oncology research, precision treatment decisions, and pharmaceutical drug-development programs.
Genetic Testing & Diagnostics
Bioarray Genetics, Inc. is a molecular diagnostics company based in Farmington, Massachusetts, United States. The company specializes in biotechnology and medical testing, having received U.S. patents supporting its lead breast cancer predictive test.
Life Sciences
Pathwork Diagnostics developed molecular diagnostic tests for cancer, notably the Tissue of Origin test, which analyzes tumor gene-expression patterns to help identify the likely primary site of metastatic cancers when the origin is unknown. Its products served pathologists and oncologists managing patients with cancers of unknown primary.
Biotechnology
Capio Biosciences is an oncology diagnostics company that develops advanced technologies for capturing and analyzing circulating tumor cells (CTCs) from whole blood. Its proprietary CapioCyte platform offers enhanced sensitivity compared to traditional methods, serving as a research tool designed to help oncologists make informed cancer treatment decisions.
Biotech
Foundation Medicine, Inc. is an American company based in Boston, Massachusetts, which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas.
Biotechnology
Mercy BioAnalytics, Inc. is a privately held biotechnology company founded in 2018 and headquartered in Waltham, Massachusetts. The company is dedicated to developing early diagnostics and detection technologies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Exosome Diagnostics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Exosome Diagnostics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →